350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)

Background

Carcinoembryonic antigen (CEACAM) or CD66+ is categorized as type N2 tumour associated neutrophils (TAN), an immunoreceptor expressed on activated neutrophils. It is also known as marker for neutrophil specific granules. This marker is expressed on tumour tissue, has strong immunosuppressive and tumour promoting acttivities including angiogenesis, invasion, and metastasis through various mechanism. This study aimed to assess intratumoural CD66B+ TAN to predict clinical treatment response in patients with diffuse large B cell lymphoma (DLBCL).

Methods

This prognostic study was conducted in Palembang, South Sumatera, Indonesia in 2020. The subjects were 18 - 70 years old DLBCL patients, enrolled by consecutive sampling using medical record. The immunohistochemistry TAN CD66b+ was examined by pathologist. Chemotherapy response was assessed clinically (hematological and radiological) after minimum two cycles of RCHOP regimen. Patients with HIV, relapsed DLBCL, other malignancies, and delayed chemotherapy were excluded.

Results

Of the 21 subjects consisted of 11 men (52,4%), the most subtype (95,2%) was DLBCL non-GCB, prognostic high-risk IPI score 42,9% and intermediate-risk 57,1%. Subjects who achieved complete remission response were 9 people (42,9%). The cut-off value for the CD66b+ TAN density was 21,7 cells/mm². A total of 76,9% of subjects with high density CD66b+ TAN did not achieve any remission (p=0.029), with sensitivity 83,3% and specificity 66,7%.

Conclusions

We found that density levels of intratumoural CD66b+ TAN in tumour tissue has significant correlation with non-responder (poor prognosis) DLBCL patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.